We are live on
!
Find out more
GPP
Great Point Partners Portfolio holdings
AUM
$435M
1-Year Est. Return
318.81%
This Fund
S&P 500
This Quarter
Est. Return
+49.13%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$642M
AUM Growth
+$54.9M
(+9.4%)
Cap. Flow
-$75.7M
Cap. Flow
% of AUM
-11.79%
Top 10 Holdings %
Top 10 Hldgs %
51.56%
Holding
44
New
10
Increased
11
Reduced
8
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viridian Therapeutics
VRDN
|
+$25.9M |
| 2 |
ESPR
Esperion Therapeutics
ESPR
|
+$19.4M |
| 3 |
DVAX
Dynavax Technologies
DVAX
|
+$16.5M |
| 4 |
ACLX
Arcellx
ACLX
|
+$16M |
| 5 |
Insmed
INSM
|
+$15.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALPN
Alpine Immune Sciences Inc
ALPN
|
+$76M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
+$31M |
| 3 |
RAPT
RAPT Therapeutics
RAPT
|
+$27.3M |
| 4 |
Alkermes
ALKS
|
+$24.3M |
| 5 |
Cytokinetics
CYTK
|
+$23M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
VistaGen Therapeutics
VTGN
$9.89M
| $9.81M | 1.53% |
1,858,735
| – | – |
|
|
TERN
27
DELISTED
Terns Pharmaceuticals
TERN
| $8.59M | 1.34% |
1,309,975
| – | – |
|
28
Immunocore
IMCR
$1.72B
| $7.47M | 1.17% |
115,000
-178,000
| -61% | -$12.2M |
|
|
AUTL
29
Autolus Therapeutics
AUTL
$397M
| $7.44M | 1.16% |
+1,166,667
| New | +$7.28M |
|
30
Puma Biotechnology
PBYI
$404M
| $7.12M | 1.11% |
1,343,628
+250,355
| +23% | +$1.35M |
|
31
Zura Bio
ZURA
$516M
| $7.09M | 1.1% |
2,757,740
-537,260
| -16% | -$1.9M |
|
|
BBOT
32
BridgeBio Oncology
BBOT
$648M
| $5.2M | 0.81% |
+500,000
| New | +$5.18M |
|
33
Spyre Therapeutics
SYRE
$8.54B
| $4.74M | 0.74% |
125,000
| – | – |
|
34
Kyverna Therapeutics
KYTX
$444M
| $3.73M | 0.58% |
+150,000
| New | +$4.19M |
|
35
Arvinas
ARVN
$518M
| $2.94M | 0.46% |
71,113
-162,969
| -70% | -$7.12M |
|
|
36
Alkermes
ALKS
$8.22B
| – | – |
-875,044
| Closed | -$24.3M |
|
37
Axsome Therapeutics
AXSM
$11.2B
| – | – |
-4,963
| Closed | -$395K |
|
|
MURA
38
DELISTED
Mural Oncology
MURA
| – | – |
-11,509
| Closed | -$68.1K |
|
39
Vaxcyte
PCVX
$7.81B
| – | – |
-360,000
| Closed | -$22.6M |
|
|
40
Ultragenyx Pharmaceutical
RARE
$2.45B
| – | – |
-648,000
| Closed | -$31M |
|
|
RAPT
41
DELISTED
RAPT Therapeutics
RAPT
| – | – |
-137,469
| Closed | -$27.3M |
|
42
Sarepta Therapeutics
SRPT
$1.57B
| – | – |
-80,000
| Closed | -$7.71M |
|
|
TRML
43
DELISTED
Tourmaline Bio
TRML
| – | – |
-672,885
| Closed | -$17.6M |
|
|
KRTX
44
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| – | – |
-30,250
| Closed | -$9.57M |
|
Similar funds
GDS
JWM
SWG
SCP
VIM
VDBMI
ACG
TECP
Great Point Partners's Q1 2024 Portfolio in Review
As of Q1 2024, Great Point Partners held 44 positions worth $642M, up 9.4% from $587M the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Great Point Partners withdrew a net $75.7M in Q1 2024, closing 9 positions and reducing 8 holdings. Its most notable exit was Ultragenyx Pharmaceutical, an estimated $31M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Great Point Partners opened a new position in Viridian Therapeutics worth $23.4M.
- Great Point Partners's largest Q1 2024 buy was Viridian Therapeutics: 1,335,000 shares worth $23.4M.
- Great Point Partners added most to Arcellx in Q1 2024, an estimated $16M increase.
- Great Point Partners's biggest Q1 2024 reduction was Alpine Immune Sciences Inc, cutting an estimated $76M.
- Great Point Partners fully exited Ultragenyx Pharmaceutical in Q1 2024, selling an estimated $31M.
- Great Point Partners's ten largest holdings make up 52% of its $642M portfolio in Q1 2024.
- Great Point Partners opened 10 new positions and closed 9 in Q1 2024.
- Great Point Partners's portfolio value rose 9.4% quarter-over-quarter to $642M.
Based on Great Point Partners's 13F filing for Q1 2024, filed 15 May 2024.